MabCure’s MAbs 94% correct in identifying ovarian cancer
Biotechnology entourage MabCure, Inc. (OTCBB: MBCI) today announced that a confirmatory look demonstrated the company’s proprietary monoclonal antibodies (MAbs) successfully identified ovarian cancer in blood (94 percent exactness and with no deceptive positives or cross-reactions with kind ovarian tumors or vigorous blood. MabCure’s serum diagnostic study is the anything else to perceive unfamiliar tumor markers or cancer fingerprints confer on solitary in ovarian cancer, the deadliest of all gynecological cancers.
“Our findings are an noted imprint in that road and also deliver outstanding implications into the to be to come maturation of cancer-specific targeted therapies.”
According to the U.S. Jingoistic Cancer Start, well-grounded 15 percent of ovarian cancers are diagnosed and treated antique, when the five-year survival velocity is 94 percent. Unfortunately, the maturity of women are diagnosed after the virus has already metastasized, when the five-year survival anyhow drops to 23 percent.
"The availability of a uninvolved blood assay with the wit to name the composure of ovarian cancer at and to apart it from harmless tumors has the unrealized to spare thousands of lives and knock down the call for fitting for dispensable surgeries," said Amnon Gonenne, Ph.D., CEO of MabCure. "Our findings are an effective become involved hurry up in that guiding and also obtain outstanding implications championing the later increase of cancer-specific targeted therapies."
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
